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Macrophages have crucial functions in initiating the inﬂammatory reaction in a strict
temporal and spatial manner to provide a “clear-up” response required for resolution.
Hormonal peptides such as melanocortins modulate macrophage reactivity and attenu-
ate inﬂammation ranging from skin inﬂammation to joint disease and reperfusion injury.
The melanocortins (e.g., adrenocorticotrophin, ACTH and αMSH) elicit regulatory proper-
ties through activation of a family of GPCRs, the melanocortin (MC) receptors; MC1–MC5.
Several studies have focused on MC1 and MC3 as anti-inﬂammatory receptors expressed
on cells of the macrophage lineage. We review here elements of the melanocortin path-
waywith particular attention tomacrophage function in anti-inﬂammatory and pro-resolving
inﬂammatory settings. Evidence shows that ACTH, αMSH, and other MC agonists can acti-
vateMC1 andMC3 onmacrophage through cAMP and/or NFκB-dependent mechanisms to
abrogate pro-inﬂammatory cytokines, chemokines, and NO and enhance anti-inﬂammatory
mediators such as IL-10 and HO-1. Melanocortins and their receptors regulate inﬂamma-
tion by inhibiting leukocyte recruitment to and interactionwith inﬂamed tissue. An intensely
exciting addition to this ﬁeld of research has been the ability of an αMSH analog; AP214 to
activate MC3 expressed on macrophage to enhance their clearance of both zymosan par-
ticles and apoptotic neutrophils thus putting melanocortins in line with other pro-resolving
mediators. The use of mouse colonies mutated or nulliﬁed for MC1 or MC3, respectively
as well as availability of selective MC receptor agonist/antagonists have been key to deci-
phering mechanisms by which elements of the melanocortin system play a role in these
phenomena. We review here melanocortin pathway components with attention to the
macrophage, reiterating receptor targets required for pro-resolving properties. The over-
all outcome will be identiﬁcation of selective MC agonists as a strategy for innovative
anti-inﬂammatory therapeutics.
Keywords: inflammation, resolution, macrophage, melanocortins, melanocortin receptor, melanocyte stimulating
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INTRODUCTION
An inﬂammatory reaction is characterized by cellular recruitment
within a tissue that ﬁrstly involves an acute phase whereby neu-
trophils act as invaders to release toxins to kill and eliminate foreign
encounters. Macrophages play a crucial role in the latter phase of
this inﬂammatory reaction. At the site of injury their ultimate
goal is counterbalance the acute phase to cease inﬂammation and
clear-up detrimental artifacts including pathogens and debris as
well as apoptotic cells from the environment. To disperse inﬂam-
mation macrophage must complete complex reactions, including
chemotaxis to move to the site of inﬂammation, phagocytose
particles or apoptotic cells (process of efferocytosis) and secrete
cytokines/chemokines, lipid mediators, reactive oxygen species,
and other factors to underpin an immune response facilitat-
ing healing/repair and return to normal homeostatic physiology.
Pathological conditions can arise as a consequence of disruption
to the sequence of events leading to resolution of inﬂamma-
tion. There has been a recent spate in research to identify and
understand these biochemical pathways and mediators enhanc-
ing the resolution of inﬂammation by macrophage in the hope
to discover new therapeutics that “switch on” this protective arm
of inﬂammation. Within the umbrella of anti-inﬂammatory and
pro-resolution mediators being investigated are the omega-3 fatty
acid derived resolvins, aspirin-related lipoxins, and the glucocorti-
coid induced proteinAnnexinA1.One other such pathway gaining
attention within this ﬁeld includes the melanocortin peptides and
their counterpart melanocortin receptors.
THE MELANOCORTIN SYSTEM
Melanocortins are derived from proteolytic cleavage of pro-
opiomelanocortin (POMC), a hormone ﬁrst thought to be
expressed only within the pituitary. Evidence now shows that
POMC is also expressed within peripheral cells and tissues
(Blalock, 1985). The enzymes proprotein convertase 1 (PC1) and
2 (PC2) belong to a conserved family of serine proteinases of the
subtilisin/kexin-type that also include furin, PC4, PACE4, PC5/6,
and PC7/LPC/PC8. Their action upon single and/or pairs of diba-
sic residues within the POMC sequence generate themelanocortin
peptides; adrenocorticotrophin (ACTH), α-, β-, γ-melanocyte
stimulating hormone. PC1 leads to generation of full-length
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pro-ACTH1–39 and β-lipotropin. PC1 then further cleaves β-
lipotropin to generate γ-lipotropin and β-endorphin, and pro-
ACTH to generateN -pro-opiocortin (POC), joining peptide (JP),
and ACTH. The down-stream actions of PC2 result in produc-
tion of ACTH1–17 and corticotrophin-like intermediate lobe pep-
tide (from ACTH), γMSH (from N -POC), and β-MSH (from
β-lipotropin). Alpha-MSH (αMSH) is generated by the com-
bined actions of carboxypeptidase (CPE), peptidylglycine alpha-
amidating mono-oxygenase (PAM), and N -acetyltransferase (N -
AT) on ACTH1–17 (Mountjoy, 2010; Figure 1).
The biological activity of the ACTH and MSH species occurs
through activation of melanocortin receptors (MC) of which ﬁve
have been cloned so far. All are seven transmembrane coupled
to s-type G-proteins thus positively coupled to adenylate cyclase;
their activation leading to increases in intracellular cAMP and,
possibly partly independently from it, down-regulation of nuclear
factor-kappa beta activation (Wikberg et al., 2000;Gantz and Fong,
2003). MC1 is the receptor expressed on melanocytes, responsi-
ble for MSH control over skin pigmentation, whereas MC2 is the
canonical ACTH receptor, expressed on adrenal cells and respon-
sible for glucocorticoid synthesis and release. The other MCs have
less clear-cut biological functions. Within the central nervous sys-
tem, MC4 is actively studied for its role in feed control, pain, and
sexual health;MC5 mightmodulate exocrine gland activity (Gantz
and Fong, 2003). MC3 might exert a control over energy metab-
olism (Butler et al., 2000), but our own work has indicated an
important modulatory role for this receptor in the control of the
host inﬂammatory response (Getting et al., 2002). Of interest here,
there is now ample evidence that MC, especially MC1, MC3, and
MC5 are distributed on peripheral cells (Catania et al., 2010).
PRODUCTION OF αMSH AND EXPRESSION OF MC
RECEPTORS BY MACROPHAGE
Melanocortins are expressed and functionally active on the
macrophage. Star et al. (1995) reported increases in cAMP accu-
mulation in RAW 264.7 macrophage (shown to express MC1 and
MC3 but not MC5) upon αMSH (pan agonist) incubation, sug-
gestive of the presence of functionally active MCs on the cell
surface (Star et al., 1995; Li and Taylor, 2008). Production of
αMSH by these cells was also noted with further augmenta-
tion of the response upon TNFα stimulation. These two lines
of evidence along with the anti-inﬂammatory action of αMSH
to reduce nitric oxide release by RAW 264.7 macrophage sug-
gest that αMSH may act in an autocrine/paracrine manner by
counteracting pro-inﬂammatory effect of cytokines (Star et al.,
1995). A similar autocrine circuit emerged in a latter study with
human monocyte/macrophage THP-1 cells. Here, incubation of
resting macrophage with an antibody recognizing MC1 on its
own increased TNFα release, with the addition of αMSH reducing
this response. Furthermore the presence of the anti-MC1 atten-
uated this inhibitory signal caused by αMSH. Collectively, these
data indicate that MC receptor agonists limit pro-inﬂammatory
cytokine production from macrophages, possibly being pivotal
also in peripheral autocrine circuits (Taherzadeh et al., 1999).
Expression of melanocortin receptors is not only restricted to
macrophage cell lines, as MC receptor mRNA has been detected
in primary rodent macrophage of alveolar (MC1 and MC3), knee
joint (MC3), mesentery (MC1 and MC3), and peritoneal (MC1,
MC3, and MC5) origin and human macrophage blood derived
macrophage (MC1, MC3, and MC5; Getting et al., 2002, 2003,
2008; Andersen et al., 2005; Leoni et al., 2008; Montero-Melendez
et al., 2011).
MELANOCORTINS RECEPTOR ACTIVATION ON
MACROPHAGE AUGMENT ANTI-INFLAMMATORY
RESPONSES
In inﬂammatory/tissue injury settings, activation of MCs can
inﬂuence a number of fundamentalmacrophage functions includ-
ing:
(1) antagonizing the release of pro-inﬂammatory cytokines,
chemokines, nitric oxide
(2) inhibiting leukocyte chemoattraction
(3) inducing release of anti-inﬂammatory cytokines and expres-
sion of heme oxygenase-1
(4) augmenting phagocytosis and efferocytosis.
It should be noted that MC receptor activation can also affect
macrophage responsiveness indirectly. For instance, the existence
of a circuit involving MC3 andMC4 within the CNS that activates
descending cholinergic ﬁbers to activate anti-inﬂammatory nico-
tinic receptors have been described (Catania, 2007). Here we will
restrict our overview on the direct effects of MC receptor on this
cell type and discuss now some of the properties listed above in
more detail.
MELANOCORTINS INHIBIT CYTOKINE PRODUCTION
The ability of melanocortin peptides to reducemacrophage release
of pro-inﬂammatory mediators and increase anti-inﬂammatory
mediators is a well-understood phenomenon with a number of
FIGURE 1 | Biochemical processing of the POMC gene product as detailed in the pituitary.The processing of POMC and products by posttranslational
modiﬁcation enzymes is depicted by arrows. Agonists of the melanocortin receptors MC1–MC5 are highlighted.
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groups contributing to this ﬁeld. For example Capsoni et al.
(2009) stimulated peripheral blood derived monocytes in vitro
with monosodium urate crystals in the presence of αMSH (pan
agonist) or (CKPV)2 (a biologically potent Lys-Pro-Val peptide
linked by Cys–Cys residues) and found signiﬁcant reductions in
IL-1β, IL-8, and TNFα release into supernatants (Capsoni et al.,
2009).We treated the RAW264.7 mouse macrophage cell line with
ACTH1–39 (pan agonist) andMTII, amore stable αMSHderivative
with higher afﬁnity for MC3 and MC4 promoted an increase in
cAMP accumulation and release of anti-inﬂammatory cytokine
IL-10, the later effect being abrogated when cells were treated
withH-89 (protein kinase A [PKA] inhibitor) suggesting signaling
down-stream of MC3 and not MC4 (as RAW264.7 did not express
MC4) was through the cAMP–PKA pathway (Lam et al., 2006). In
similar experiments both ACTH and MTII elicited in a cAMP–
PKA dependent manner cytoprotective and anti-inﬂammatory
heme oxygenase-1 (HO-1) but not heme oxygenase-2, heat shock
protein 70 and 90 in RAW267.4 cells (Lam et al., 2005). Mandrika
et al. (2001) showed dual signaling mechanism by which αMSH
inhibited nitric oxide production by RAW267.4 macrophage. One
pathway dependent of MC1/cAMP activation and the other caus-
ing inhibition of NFκB translocation in a cAMP-independent
manner. Other specialized cells of the macrophage lineage such
as microglia treated with αMSH or ACTH substantially reduced
TNFα, IL-6, and nitric oxide increases caused by LPS+ IFNγ acti-
vation, suggesting thatMC peptides exert their anti-inﬂammatory
actions on peripheral as well as central cells of the phagocytic lin-
eage. There is evidence of active MC receptors because the same
study reported that αMSH could induce cAMP accumulation in
both resting and activated microglia (Delgado et al., 1998).
Rat macrophage isolated from gouty knee joints also accu-
mulated intracellular cAMP upon treatment with melanocortin
peptide; ACTH (Getting et al., 2002). More recently functionality
ofMC receptors by cAMP readout onmurine alveolarmacrophage
was conﬁrmed after incubation with αMSH, [D-Trp8]γMSH
(MC3/MC5 agonist), and MSO5 (MC1 agonist; Getting et al.,
2008; Joseph et al., 2010). Together these studies suggest that
the cAMP pathway represents a common underlying mechanism
for melanocortin to deliver anti-inﬂammatory effects. Manna and
Aggarwal stimulated human monocytes with various inﬂamma-
tory agents including TNFα, LPS, ceramide, and okadaic acid to
obtainNFκB activation,whichwas diminished in cells treatedwith
αMSH(Manna andAggarwal, 1998). The agonistic effect appeared
to be cAMP-dependent such that inhibitors of adenylate cyclase
and PKA reversed the inhibitory effect of αMSH. Furthermore
αMSH inhibition of degradation of the NFκB inhibitory subunit
IκBα and nuclear translocation of p65 subunit were also noted
(Manna and Aggarwal, 1998).
Collectively these data appear to show that the anti-
inﬂammatory actions of αMSH are dependent on MC1, MC3,
and/orMC5 receptor activation and triggers inhibition of NFκB in
a cAMP-dependent and independent manner through molecular
links which are yet to be deciphered.
MELANOCORTINS INHIBIT CHEMOTAXIS OF LEUKOCYTES
As discussed so far,melanocortins are able to dampenmacrophage
release of pro-inﬂammatory mediators in inﬂammatory settings.
These phenomena were exploited further by Capsoni et al.
(2009) who showed that melanocortins could inﬂuence the
monocytes ability to recruit and prime neutrophils. Chemotaxis
of neutrophils treated with αMSH or (CKPV)2 was examined
using a boyden chamber assay and supernatants collected from
monosodium urate crystal-stimulated monocytes as the source
of chemoattractants. Chemotaxis was signiﬁcantly reduced in
neutrophils treated with agonist compared to controls. Further-
more reduced chemiluminescence (as a marker of reactive oxygen
intermediates) production by pre-treated primed neutrophils was
observed, in line with other studies showing melanocortin pep-
tides can inhibit chemotaxis and generation of reactive oxygen
species (Catania et al., 1996; Getting et al., 1999a; Capsoni et al.,
2009).
To decipher what role MC3 has on leukocyte interaction with
the inﬂamed mesentery, experiments were performed using phar-
macological agents andmice nulliﬁed for MC3 where the superior
mesenteric artery was occluded for 35min followed by reopening
to allow for blood reperfusion. Treatment with [D-Trp8]γMSH,
a MC3/MC5 agonist did not alter cell rolling but decreased cell
adhesion and emigration compared to vehicle control an effect
not observed in Mc3r−/− mice. These data were mirrored by
augmented KC and MCP-1 responses in mesenteric tissues of
Mc3r−/− mice suggesting MC3 is able to regulate leukocyte
interaction with postcapillary venules and regulate levels of pro-
inﬂammatory molecules in ischemia reperfusion injured tissues
(Leoni et al., 2008). Moreover, whilst agonizing more than one
MC receptor, the vasculoprotective properties of [D-Trp8]γMSH
are solely transduced by MC3.
Of interest, the modulation of chemokines occurred in the
tissue and not with respect to plasma levels, moreover, levels of
the cytokines IL-1β and TNFα were not affected by pharmaco-
logical treatment with [D-Trp8]γMSH or absence of the MC3
gene. The “selective” effect on tissue chemokine levels may be sec-
ondary to inhibition of activation of resident cells, such as tissue
macrophages and connective tissue type mast cells (Kubes and
Granger, 1996; Tailor et al., 1999).
In similar experimental settings, the effects of a small molecule
MC1 agonist, compoundBMS-470539 (Kang et al., 2006) inhibited
cell adhesion,and emigration,an effect thatwas lacking in yellowe/e
mice. Interestingly, unlike Mc3r−/− mice, the yellowe/e mice
(expressing non-functional MC1) displayed a comparable leuko-
cyte adhesion and emigration response to wild types. Collectively
these two studies identify a complex scenario whereby although
bothMC1 andMC3 are expressed in the inﬂamedmesentery,MC1
may not be endogenously activated in ischemia reperfusion injury
whereas MC3 is both exogenously and endogenously activated in
this setting (Leoni et al., 2010). Future studies addressing the hypo-
thetical generation of selective agonists post-ischemia reperfusion
might help deciphering this apparent discrepancy.
ACTIVATION OF MC3 IS A KEY MEDIATOR OF ANTI-INFLAMMATORY
EFFECTS IN MACROPHAGES
Until a decade ago, the mainstream school of thought was that the
anti-inﬂammatory actions of melanocortin agonists were solely
through MC1 activation (Lipton and Catania, 1997; Luger et al.,
2003).We used twomouse colonies, one bearing a non-functional
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MC1 (yellowe/e mice) and the other knocked out for MC3
(Mc3r−/− mice), to conclude that MC3 can be engaged by
agonists with anti-inﬂammatory properties. Cultured primary
peritoneal macrophage from yellowe/e mice were treated with
[D-Trp8]γMSH displaying a dose-dependent increase in cAMP
accumulation, an effect reversed in the presence of an antibody to
MC3. The release of the chemokine KC was abrogated in the pres-
ence of [D-Trp8]γMSH with the antagonist agouti related protein
(AGRP) abolishing the inhibitory effect.
In another study mice pre-treated with ACTH were injected
with MSU crystals to induce peritonitis. A reduced accumulation
of PMN was observed in the peritoneal cavity of mice treated
with ACTH compared to vehicle control, data that was mirrored
by decreased levels of KC also within the cavity. Interestingly
co-administration of SHU9119 (an MC3/MC4 antagonist) with
ACTH inhibited the agonists effects suggesting ACTH was acting
through MC3 and further conﬁrmed by the detection of MC3 but
not MC4 at the mRNA transcript level on peritoneal macrophage
(Getting et al., 1999b). At a latter date, Getting et al. (2003) in
the same peritonitis model using more selective MC3 agonists
and yellowe/e mice conﬁrmed that indeed agonism at MC3 inhib-
ited pro-inﬂammatory cytokines (IL-1) and chemokines (KC) and
accumulation of neutrophils in the inﬂamed peritoneal cavity
(Getting et al., 2003). Collectively these data suggest MC3 more
than MC1 (at least in mouse) to be pivotal in bringing about the
anti-inﬂammatory effects observed following treatmentwith these
agonists (Getting et al., 1999b, 2003, 2006).
MC3 REGULATES MACROPHAGE DIFFERENTIATION TO OSTEOCLASTS
DURING INFLAMMATORY ARTHRITIS
More recently MC3 has been implicated in the regulation of
macrophage precursor differentiation to osteoclasts. Inﬂamma-
tory arthritis was induced by injection of an arthritogenic serum
into wild type and Mc3r−/−, observing a higher prevalence and
severity of disease observed in the latter genotype (Patel et al.,
2010a). In a series of real time PCR analyses of extracts from the
mouse ankle joint, a discrete set of inﬂammatory genes (13 out of
96) were upregulated in Mc3r−/− including IL-1β, IL-6, NOS2,
CCR4, CXCR3, CCL2 as compared to wild types. It is worthy to
note here thatmajormacrophage secretory products include IL-1β
and IL-6 (Gordon, 2003).
Upon microscopic analyses of the ankle joints, a signiﬁcantly
higher number of joints were affected by bone erosion, as indicated
by histological scores and number of TRAP-positive osteoclasts
within the Mc3r−/− joint. This observation was corroborated by
the higher levels of RANKL (a key driver of osteoclast formation)
mRNA inMc3r−/− ankle joints (Lacey et al., 1998). Although the
exact mechanism was not characterized, some conclusion could
be reached by the study of osteoclast formation in vitro. Bone
marrow-derived macrophage from wild type and Mc3r−/− mice
were differentiated to osteoclasts in the presence of M-CSF and
RANKL. A defect was noted such that a higher number of osteo-
clasts were generated from macrophage absent of the MC3 gene
compared to MC3 sufﬁcient cells. The Mc3r−/− osteoclasts dis-
played an increased “eating” ability such that when cultured on
calcium phosphate coated wells signiﬁcantly more resorption pits
could be observed and quantiﬁed. Interestingly Mc3r−/− cells
had increased and sustained RANKL-mediated NFκB signaling
compared to wild types; this ﬁnding could provide mechanistic
support to the increased CCL2 synthesis observed by these cells
(Patel et al., 2010a). Together with the study by Cornish et al.
(2003), our work implicates a role for melanocortins and their
melanocortin receptors in the regulation of macrophage differen-
tiation to specialized cells, example being here the osteoclast. It is
plausible that MCs may modulate macrophage differentiation in
other specialized cells such as the microglia or Kupffer cells, with
further implications for their therapeutic potential.
MC3 ACTIVATION ENHANCES RESOLUTION OF INFLAMMATION
Resolution of inﬂammation is an important process required to
reset tissue/cells to a state of normalization after insult/injury.
During this process a number of endogenous pathways are acti-
vated in order to regain homeostatic balance after inﬂammation.
An exciting enhancement to the ﬁeld of melanocortin biology in
inﬂammation has been the recent ﬁnding that AP214, a modiﬁed
αMSH analog, possesses prophagocytic and pro-resolving effects
(Montero-Melendez et al., 2011), in line with the proﬁle reported
for resolvins and lipoxins (Schwab et al., 2007).
AP214 inhibits neutrophil recruitment in the zymosan peri-
tonitis model, an effect that could be due, at least in part, to amod-
ulation of macrophage phagocytic abilities of the particles. In vitro,
AP214-treated biogel-elicited macrophages were incubated with
zymosan particles to determine the percentage of phagocytic cells
and number of ingested particles, observing an increment in both
parameters. Such an effect of AP214was also observedwith respect
to efferocytosis since this MSH analog augmented phagocytosis
of human apoptotic neutrophils by mouse macrophages, an effect
that was absent whenMc3r−/−macrophages were used. In in vivo
settings, injection of apoptotic neutrophils into murine peritoneal
cavities pre-treated with AP214 led to an increase in macrophage
ingestion of neutrophils compared to vehicle control. This recent
study has uncovered a new angle in which melanocortins and
their receptors can affect the inﬂammatory reaction providing
strong evidence for genuine pro-resolving activities centered on
tight regulation of macrophage functions.
CONCLUSION
In this review we have highlighted the importance of
melanocortins and their receptors in modulating the macrophage
function in inﬂammation and tissue injury (see Figure 2). We
have seen that MC activation does not merely reduce production
of pro-inﬂammatory mediators, but can regulate cell differentia-
tion as well as chemotaxis of leukocytes. Excitingly,melanocortins
can now be added to the plethora of pro-resolution mediators by
way of their ability to augment phagocytosis and efferocytosis;
we predict these portfolio of properties will deﬁne other func-
tions/biological properties of melanocortins in other aspects of
resolution of inﬂammation in the years to come.
What does this mean for the development of melanocortin-
based therapies? Noteworthy, ACTH has been used as early as the
1940s for the treatment of gouty and rheumatoid arthritis, yet as
discussed above never were the mechanisms of actions deciphered
until the recent decade (Hench et al., 1949; Gutman andYu, 1950).
What does remain in its infancy is the pattern in which MCs may
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FIGURE 2 | Melanocortin receptor type 3 activation on macrophage (mφ) functions Activation of MC3 by endogenous or selective synthetic agonists
leads to regulation of osteoclast generation, control of pro-inflammatory and anti-inflammatory mediators and resolution of inflammation by
efferocytosis and phagocytosis.
be expressed in speciﬁc disease, nevertheless this area of research
and drug development has become particularly eye-catching as
seen with the development of AP214 for the treatment of post-
surgical kidney injury following cardiac heart surgery in phase II
trials (www.clinicaltrials.gov). Other melanocortin-based thera-
pies are in the development pipeline for biotechnology companies
with emphasis on obesity and sexual dysfunction as disease targets
(Patel et al., 2010b).
We envisage over the next decade new drugs based on the
melanocortin peptides – speciﬁcally targeting MC3 – to be devel-
oped and designed for the treatment of inﬂammatory conditions.
These drugs would be better tolerated with a lower burden of side-
effects as they would mimic the body’s way of naturally abating
inﬂammation to promote pro-resolving and anti-inﬂammatory
mediators.
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